全文获取类型
收费全文 | 34437篇 |
免费 | 1954篇 |
国内免费 | 184篇 |
专业分类
耳鼻咽喉 | 344篇 |
儿科学 | 468篇 |
妇产科学 | 370篇 |
基础医学 | 4562篇 |
口腔科学 | 1029篇 |
临床医学 | 2211篇 |
内科学 | 8404篇 |
皮肤病学 | 858篇 |
神经病学 | 2592篇 |
特种医学 | 1364篇 |
外科学 | 5976篇 |
综合类 | 165篇 |
一般理论 | 1篇 |
预防医学 | 1081篇 |
眼科学 | 662篇 |
药学 | 2578篇 |
中国医学 | 46篇 |
肿瘤学 | 3864篇 |
出版年
2023年 | 180篇 |
2022年 | 372篇 |
2021年 | 642篇 |
2020年 | 364篇 |
2019年 | 480篇 |
2018年 | 625篇 |
2017年 | 535篇 |
2016年 | 589篇 |
2015年 | 632篇 |
2014年 | 801篇 |
2013年 | 998篇 |
2012年 | 1505篇 |
2011年 | 1645篇 |
2010年 | 958篇 |
2009年 | 871篇 |
2008年 | 1457篇 |
2007年 | 1461篇 |
2006年 | 1521篇 |
2005年 | 1608篇 |
2004年 | 1475篇 |
2003年 | 1513篇 |
2002年 | 1399篇 |
2001年 | 1313篇 |
2000年 | 1358篇 |
1999年 | 1226篇 |
1998年 | 446篇 |
1997年 | 358篇 |
1996年 | 333篇 |
1995年 | 298篇 |
1994年 | 264篇 |
1993年 | 260篇 |
1992年 | 829篇 |
1991年 | 740篇 |
1990年 | 740篇 |
1989年 | 713篇 |
1988年 | 715篇 |
1987年 | 629篇 |
1986年 | 622篇 |
1985年 | 614篇 |
1984年 | 412篇 |
1983年 | 329篇 |
1982年 | 164篇 |
1979年 | 323篇 |
1978年 | 205篇 |
1977年 | 154篇 |
1975年 | 150篇 |
1974年 | 220篇 |
1973年 | 151篇 |
1972年 | 168篇 |
1971年 | 149篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
Jun Agata Nobuyuki Ura Hideaki Yoshida Yasuyuki Shinshi Haruki Sasaki Masaya Hyakkoku Shinya Taniguchi Kazuaki Shimamoto 《Hypertension research》2006,29(11):865-874
Angiotensin II receptor blockers (ARBs) are widely used for the treatment of hypertension. It is believed that treatment with an ARB increases the level of plasma angiotensin II (Ang II) because of a lack of negative feedback on renin activity. However, Ichikawa (Hypertens Res 2001; 24: 641-646) reported that long-term treatment of hypertensive patients with olmesartan resulted in a reduction in plasma Ang II level, though the mechanism was not determined. It has been reported that angiotensin 1-7 (Ang-(1-7)) potentiates the effect of bradykinin and acts as an angiotensin-converting enzyme (ACE) inhibitor. It is known that ACE2, which was discovered as a novel ACE-related carboxypeptidase in 2000, hydrolyzes Ang I to Ang-(1-9) and also Ang II to Ang-(1-7). It has recently been reported that olmesartan increases plasma Ang-(1-7) through an increase in ACE2 expression in rats with myocardial infarction. We hypothesized that over-expression of ACE2 may be related to a reduction in Ang II level and the cardioprotective effect of olmesartan. Administration of 0.5 mg/kg/day of olmesartan for 4 weeks to 12-week-old stroke-prone spontaneously hypertensive rats (SHRSP) significantly reduced blood pressure and left ventricular weight compared to those in SHRSP given a vehicle. Co-administration of olmesartan and (D-Ala7)-Ang-(1-7), a selective Ang-(1-7) antagonist, partially inhibited the effect of olmesartan on blood pressure and left ventricular weight. Interestingly, co-administration of (D-Ala7)-Ang-(1-7) with olmesartan significantly increased the plasma Ang II level (453.2+/-113.8 pg/ml) compared to olmesartan alone (144.9+/-27.0 pg/ml, p<0.05). Moreover, olmesartan significantly increased the cardiac ACE2 expression level compared to that in Wistar Kyoto rats and SHRSP treated with a vehicle. Olmesartan significantly improved cardiovascular remodeling and cardiac nitrite/ nitrate content, but co-administration of olmesartan and (D-Ala7)-Ang-(1-7) partially reversed this anti-remodeling effect and the increase in nitrite/nitrate. These findings suggest that olmesartan may exhibit an ACE inhibitory action in addition to an Ang II receptor blocking action, prevent an increase in Ang II level, and protect cardiovascular remodeling through an increase in cardiac nitric oxide production and endogenous Ang-(1-7) via over-expression of ACE2. 相似文献
12.
13.
Kosuke Kaida Masaya Takahashi Torbj?rn Akerstedt Akinori Nakata Yasumasa Otsuka Takashi Haratani Kenji Fukasawa 《Clinical neurophysiology》2006,117(7):1574-1581
OBJECTIVE: The Karolinska sleepiness scale (KSS) is frequently used for evaluating subjective sleepiness. The main aim of the present study was to investigate the validity and reliability of the KSS with electroencephalographic, behavioral and other subjective indicators of sleepiness. METHODS: Participants were 16 healthy females aged 33-43 (38.1+/-2.68) years. The experiment involved 8 measurement sessions per day for 3 consecutive days. Each session contained the psychomotor vigilance task (PVT), the Karolinska drowsiness test (KDT-EEG alpha & theta power), the alpha attenuation test (AAT-alpha power ratio open/closed eyes) and the KSS. RESULTS: Median reaction time, number of lapses, alpha and theta power density and the alpha attenuation coefficients (AAC) showed highly significant increase with increasing KSS. The same variables were also significantly correlated with KSS, with a mean value for lapses (r=0.56). CONCLUSIONS: The KSS was closely related to EEG and behavioral variables, indicating a high validity in measuring sleepiness. SIGNIFICANCE: KSS ratings may be a useful proxy for EEG or behavioral indicators of sleepiness. 相似文献
14.
Shoji Kubo Hiroaki Kinoshita Kazuhiro Hirohashi Takatsugu Yamamoto 《Journal of Hepato-Biliary-Pancreatic Surgery》1995,2(1):85-89
A case of cystadenocarcinoma of the liver is reported. The patient was a 73-year-old woman in whom a tumor was detected in
the lateral segment of the liver during a health examination. Ultrasonograms and computed tomograms showed a multilocular
cystic mass. Magnetic resonance imaging (MRI) showed a multilocular lowintensity mass, including a high-intensity portion
and a portal branch compressed by the tumor. MRI with gadolinium showed an enhanced cyst wall. The cystic part of the tumor
became smaller and the solid part became larger over a 1-month period, indicating that the tumor was malignant. Subsegmentectomy
(S3) was performed and cystadenocarcinoma with cystadenoma was diagnosed by histopathological examination. Identification of
changes in the appearance of a tumor should be helpful for the differential diagnosis of cystadenoma and cystadenocarcinoma. 相似文献
15.
T. Akatsu T. Murakami K. Ono M. Nishikawa E. Tsuda S.-I. Mochizuki N. Fujise K. Higashio K. Motoyoshi M. Yamamoto N. Nagata 《BONE》1998,23(6):495-498
Osteoclastogenesis inhibitory factor (OCIF) is a novel secreted protein that inhibits osteoclastogenesis both in vitro and in vivo. In this study, we examined the effects of OCIF on serum calcium (Ca) concentrations in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. In normal mice, a single intraperitoneal injection of OCIF reduced serum Ca levels in a dose-dependent manner. Significant decrease in serum Ca (by 1.6 ± 0.3 mg/dL, n = 5) was observed 2 h after the injection of OCIF at 20 mg/kg and the hypocalcemic effect continued for up to 12 h. Serum phosphate (Pi) concentrations also decreased in response to OCIF. Urinary excretion of Ca, Pi, and creatinine did not change significantly after injection of OCIF or vehicle. In hypercalcemic, tumor-bearing nude mice, a single intraperitoneal injection of OCIF at 20 mg/kg resulted in a dramatic decrease in serum Ca (maximal decrease 2.8 ± 0.37 mg/dL, n = 11), which continued for up to 24 h. The results suggest that OCIF decreased serum Ca through its inhibitory effect on bone resorption. Furthermore, it is suggested that OCIF has therapeutic potential for the treatment of hypercalcemic conditions such as malignancy-associated hypercalcemia. 相似文献
16.
Xin Mei Jiang Akio Ohnishi Tatsunori Yamamoto Yoshiyuki Murai Akira Awaya Masato Ikeda 《Acta neuropathologica》1995,90(2):130-134
One of the pyrimidine compounds, 2-piperadino-6-methyl-5-oxo-5,6-dihydro(7H)pyrrolo[3,4-d]pyrimidine (MS-818), has neurotropic effects in vitro. Therefore, we studied the effect of MS-818 on the regeneration of the peroneal nerve in C57BL/6J mice after a crush injury. Two test groups, which received a daily intraperitoneal injection of 5 mg/kg or 10 mg/kg MS-818, respectively, were compared with controls, which received daily intraperitoneal injections of physiological saline, over a 14-day period. The maximum foot-width ratio (crushed side/uncrushed side) was obtained on days 1, 8 and 14 after the crush injury, and the various morphometric parameters were evaluated at both 5 and 10 mm distal to the proximal portion of the crush site. The significant effects of MS-818 included a larger maximum foot width (P<0.04) and a greater number of unmyelinated axons per nerve at both levels (P<0.003) in both test groups than in controls. MS-818 had no significant effects on body weight, the increase of total transverse fascicular area after the crush injury, the total number of myelinated fibers with their size distributions, or the number of nuclei of Schwann cells and macrophages. Therefore, we conclude that MS-818 promotes axonal sprouting and elongation after a crush injury in mice. 相似文献
17.
H Murakami M Togawa S Takahashi N Kasahara J Yamamoto N Matsuura Y Koshiyama Y Ino M Oda 《Arzneimittel-Forschung》1990,40(12):1352-1358
The effects of FUT-187 (6-amidino-2-naphthyl 4-[(4,5-dihydro-1H-imidazol-2-yl)amino]benzoate dimethanesulfonate, CAS 103926-82-5), a novel synthetic protease inhibitor, were examined in experimental rat and canine models of pancreatitis. 1. FUT-187 significantly increased the survival of rats with trypsin- and phospholipase A2-induced pancreatitis in a dose-dependent manner (10-100 mg/kg, p.o.). 2. FUT-187 decreased plasma enzymatic activity reflecting the degree of pancreatitis in rats with ethionine-induced pancreatitis, and showed a tendency to ameliorate histopathological changes in the pancreas (10-100 mg/kg p.o.). 3. FUT-187 (10 mg/kg) produced an obvious improvement of various biochemical parameters of pancreatitis and also reduced histopathological changes in the pancreas in animals with experimental pancreatitis produced by the closed duodenal loop method. In addition, FUT-187 significantly increased the survival of dogs when given by direct administration into the lumen of the closed duodenal loop. The therapeutic effects of FUT-187 in experimental pancreatitis were nearly equal in most instances to those of camostat mesilate. Thus, FUT-187 would appear to be an effective new agent for the treatment of pancreatitis. 相似文献
18.
19.
20.